ReviewCurrent diabetes reports2018
The Landscape of Diabetic Kidney Disease in the United States.
Review in Current diabetes reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Predictive Models for Hypoglycemia Risk in Haemodialysis Patients With Diabetic Kidney Disease: Systematic Review and Meta-Analysis.Journal of clinical nursing · 2026Pooled it
- Rate and risk factors of kidney function decline among South Asians with type 2 diabetes: analysis of the CARRS Trial.BMJ open diabetes research & care · 2024Trial
- Exploring mHealth potential to improve kidney function: secondary analysis of a randomized trial of diabetes self-care in diverse adults.BMC nephrology · 2022Trial
- Primary Care Providers' Acceptance of Pharmacists' Recommendations to Support Optimal Medication Management for Patients with Diabetic Kidney Disease.Journal of general internal medicine · 2020Trial
- Exploring the renoprotective potential of Beta vulgaris in diabetic nephropathy: an integrated network pharmacology, molecular docking and dynamics simulation study.Molecular diversity · 2026Article
- Dysregulation of the miR-4286 in diabetic kidney disease and its role in inflammatory response.Diabetology & metabolic syndrome · 2026Article
- Efficacy and safety of finerenone in diabetic kidney disease: Latin American experience from FINDKDLATAM trial.World journal of nephrology · 2026Article
- Awareness and Perceived Risk Factors of Chronic Kidney Disease Among Patients with Diabetes in the Northern Borders of Saudi Arabia: Implications for a Strategic Monitoring and Management Plan.Diseases (Basel, Switzerland) · 2026Article
- Trends and Independent Correlates of Chronic Kidney Disease Awareness in US Adults: NHANES 1999-2020.American journal of nephrology · 2025Article
- The nonsteroidal MR antagonist finerenone reverses Western diet-induced kidney disease by regulating mitochondrial and lipid metabolism and inflammation.American journal of physiology. Renal physiology · 2025Article
- Comparative Effects of Dulaglutide and Semaglutide on Renal Function Decline and Proteinuria Reduction in Diabetic Patients: A Retrospective Cohort Study.Journal of clinical medicine · 2025Article
- The Role of miR-802 in Diabetic Kidney Disease: Diagnostic and Therapeutic Insights.International journal of molecular sciences · 2025Review
- Control of Mitochondrial Quality: A Promising Target for Diabetic Kidney Disease Treatment.Kidney international reports · 2025Review
- Article
- Social deprivation and diabetic kidney disease: A European view.Journal of diabetes investigation · 2024Review
- Gender Differences in the Incidence of Nephropathy and Changes in Renal Function in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Diabetic Kidney Disease Prevention Care Model Development.Clinical diabetes : a publication of the American Diabetes Association · 2024Article
- Identification and validation of immune and cuproptosis - related genes for diabetic nephropathy by WGCNA and machine learning.Frontiers in immunology · 2024Article
- Diabetes Pay-for-Performance Program Participation and Dialysis Risk in Relation to Educational Attainment: A Retrospective Cohort Study.Healthcare (Basel, Switzerland) · 2023Article
- Development of a clinical automatic calculation of hypoglycemia during hemodialysis risk in patients with diabetic nephropathy.Diabetology & metabolic syndrome · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe purposes of this review are to identify population characteristics of important risk factors for the development and progression of diabetic kidney disease (DKD) in the United States and to discuss barriers and opportunities to improve awareness, management, and outcomes in patients with DKD. RECENT
findingsThe major risk factors for the development and progression of DKD include hyperglycemia, hypertension, and albuminuria. DKD disproportionately affects minorities and individuals with low educational and socioeconomic status. Barriers to effective management of DKD include the following: (a) limited patient and healthcare provider awareness of DKD, (b) lack of timely referrals of patients to a nephrologist, (c) low patient healthcare literacy, and (d) insufficient access to healthcare and health insurance. Increased patient and physician awareness of DKD has been shown to enhance patient outcomes. Multifactorial and multidisciplinary interventions targeting multiple risk factors and patient/physician education may provide better outcomes in patients with DKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.